Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program
- PMID: 22929085
- PMCID: PMC3462144
- DOI: 10.1186/1471-2334-12-200
Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program
Abstract
Background: Acinetobacter baumannii complex (ABC) has emerged as an important pathogen causing a variety of infections. Longitudinal multicenter surveillance data on ABC from different sources in Taiwan have not been published. Using data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) conducted biennially, we investigated the secular change in resistance of 1640 ABC from 2002 to 2010 (TSAR period III to VII) to different antimicrobial agents and identified factors associated with imipenem-resistant and extensively drug-resistant ABC (IRABC and XDRABC).
Methods: Isolates were collected by TSAR from the same 26 hospitals located in all 4 regions of Taiwan. Minimum inhibitory concentrations (MIC) were determined by reference broth microdilution method. Isolates nonsusceptible to all tested aminoglycosides, fluoroquinolones, β-lactam, β-lactam/β-lactam inhibitors, and carbapenems were defined as extensively drug-resistant (XDR). Multivariate logistic regression analysis was performed to assess the relationship between predictor variables among patients with resistant ABC and patients with non-resistant ABC.
Results: The prevalence of IRABC increased from 3.4% in 2002 to 58.7% in 2010 (P < 0.001; odds ratio [OR], 2.138; 95% confidence interval [CI], 1.947 to 2.347) and that of XDRABC increased from 1.3% in 2002 to 41.0% in 2010 (P < 0.001; OR, 1.970; 95% CI, 1.773-2.189). The rates of non-susceptibility to other antimicrobial agents remained high (>55%) over the years with some fluctuations before and after TSAR V (2006) on some agents. Multivariate analysis revealed that recovery from elderly patients, origins other than blood, from ICU settings, or geographic regions are independent factors associated with IRABC and XDRABC. Although the prevalence of XDRABC increased in all four regions of Taiwan over the years, central Taiwan had higher prevalence of XDRABC starting in 2008. Susceptibility to polymyxin remained high (99.8%).
Conclusions: This longitudinal multicenter surveillance program revealed significant increase and nationwide emergence of IRABC and XDRABC in Taiwan over the years. This study also identified factors associated with IRABC and XDRABC to help guide empirical therapy and at-risk groups requiring more intense interventional infection control measures with focused surveillance efforts.
Figures



Similar articles
-
Trends in Drug Resistance of Acinetobacter baumannii over a 10-year Period: Nationwide Data from the China Surveillance of Antimicrobial Resistance Program.Chin Med J (Engl). 2017 Mar 20;130(6):659-664. doi: 10.4103/0366-6999.201601. Chin Med J (Engl). 2017. PMID: 28303847 Free PMC article.
-
Molecular epidemiology and antimicrobial resistance phenotypes of Acinetobacter baumannii isolated from patients in three hospitals in southern Vietnam.J Med Microbiol. 2017 Jan;66(1):46-53. doi: 10.1099/jmm.0.000418. J Med Microbiol. 2017. PMID: 28198682
-
Molecular epidemiology, antimicrobial susceptibility and carbapenemase resistance determinants among Acinetobacter baumannii clinical isolates in Taiwan.J Microbiol Immunol Infect. 2014 Aug;47(4):324-32. doi: 10.1016/j.jmii.2013.03.008. Epub 2013 May 28. J Microbiol Immunol Infect. 2014. PMID: 23726465
-
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15. Microb Pathog. 2019. PMID: 30562602
-
Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?Expert Rev Anti Infect Ther. 2024 Dec;22(12):1171-1187. doi: 10.1080/14787210.2024.2412637. Epub 2024 Oct 9. Expert Rev Anti Infect Ther. 2024. PMID: 39381911 Review.
Cited by
-
Epidemiology and Cytokine Levels among Children with Nosocomial Multidrug-Resistant Acinetobacter baumannii Complex in a Tertiary Hospital of Eastern China.PLoS One. 2016 Aug 31;11(8):e0161690. doi: 10.1371/journal.pone.0161690. eCollection 2016. PLoS One. 2016. PMID: 27579592 Free PMC article. Clinical Trial.
-
Class 1 integrons and antibiotic resistance of clinical Acinetobacter calcoaceticus-baumannii complex in Poznań, Poland.Curr Microbiol. 2014 Sep;69(3):258-62. doi: 10.1007/s00284-014-0581-0. Epub 2014 Apr 17. Curr Microbiol. 2014. PMID: 24740302 Free PMC article.
-
Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii.Front Microbiol. 2015 Mar 25;6:231. doi: 10.3389/fmicb.2015.00231. eCollection 2015. Front Microbiol. 2015. PMID: 26284030 Free PMC article.
-
Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: Is there any benefit of adding tigecycline to aerosolized colistimethate sodium?Medicine (Baltimore). 2018 Sep;97(39):e12278. doi: 10.1097/MD.0000000000012278. Medicine (Baltimore). 2018. PMID: 30278498 Free PMC article.
-
Acinetobacter seifertii Isolated from China: Genomic Sequence and Molecular Epidemiology Analyses.Medicine (Baltimore). 2016 Mar;95(9):e2937. doi: 10.1097/MD.0000000000002937. Medicine (Baltimore). 2016. PMID: 26945401 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical